Growth factor activation in response to regorafenib.

Our laboratory uses in vitro and in vivo cellular and experimental models to study signal transduction and its basic, translational and clinical utilities. Multikinase inhibitors used in medical oncology include sorafenib and sunitinib. We describe here transcriptomic data gathered from the study of human cancer cells treated with the next-generation multikinase growth factor inhibitor, regorafenib.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-10-31
DOI
https://doi.org/10.5281/zenodo.23837188
Primary Topic
Fibroblast Growth Factor Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
preprint

Growth factor activation in response to regorafenib.

Shahan Mamoor
Zenodo (CERN European Organization for Nuclear Research)
Fibroblast Growth Factor Research
preprint

Growth factor activation in response to regorafenib.

Shahan Mamoor
preprint en

Abstract

Our laboratory uses in vitro and in vivo cellular and experimental models to study signal transduction and its basic, translational and clinical utilities. Multikinase inhibitors used in medical oncology include sorafenib and sunitinib. We describe here transcriptomic data gathered from the study of human cancer cells treated with the next-generation multikinase growth factor inhibitor, regorafenib.

Zenodo (CERN European Organization for Nuclear Research)
Fibroblast Growth Factor Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Growth factor activation in response to regorafenib. — Shahan Mamoor · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS